Dokument: Characterizing the mutational burden, DNA methylation landscape, and proteome of germ cell tumor-related somatic-type malignancies to identify the tissue-of-origin, mechanisms of therapy resistance, and druggable targets
| Titel: | Characterizing the mutational burden, DNA methylation landscape, and proteome of germ cell tumor-related somatic-type malignancies to identify the tissue-of-origin, mechanisms of therapy resistance, and druggable targets | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=68823 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20250226-120212-4 | |||||||
| Kollektion: | Publikationen | |||||||
| Sprache: | Englisch | |||||||
| Dokumententyp: | Wissenschaftliche Texte » Artikel, Aufsatz | |||||||
| Medientyp: | Text | |||||||
| Autoren: | Bremmer, Felix [Autor] Pongratanakul, Pailin [Autor] Skowron, Margaretha A. [Autor] Che, Yue [Autor] Richter, Annika [Autor] Küffer, Stefan [Autor] Reuter-Jessen, Kirsten [Autor] Bohnenberger, Hanibal [Autor] Pauls, Stella [Autor] Kresbach,Catena [Autor] | |||||||
| Dateien: |
| |||||||
| Beschreibung: | Background
Germ cell tumors (GCT) might undergo transformation into a somatic-type malignancy (STM), resulting in a cell fate switch to tumors usually found in somatic tissues, such as rhabdomyosarcomas or adenocarcinomas. STM is associated with a poor prognosis, but the molecular and epigenetic mechanisms triggering STM are still enigmatic, the tissue-of-origin is under debate and biomarkers are lacking. Methods To address these questions, we characterized a unique cohort of STM tissues on mutational, epigenetic and protein level using modern and high-throughput methods like TSO assays, 850k DNA methylation arrays and mass spectrometry. Results and conclusions For the first time, we show that based on DNA methylation and proteome data carcinoma-related STM more closely resemble yolk-sac tumors, while sarcoma-related STM resemble teratoma. STM harbor mutations in FGF signaling factors (FGF6/23, FGFR1/4) highlighting the corresponding pathway as a therapeutic target. Furthermore, STM utilize signaling pathways, like AKT, FGF, MAPK, and WNT to mediate molecular functions coping with oxidative stress, toxin transport, DNA helicase activity, apoptosis and the cell cycle. Collectively, these data might explain the high therapy resistance of STM. Finally, we identified putative novel biomarkers secreted by STM, like EFEMP1, MIF, and DNA methylation at specific CpG dinucleotides. | |||||||
| Rechtliche Vermerke: | Originalveröffentlichung:
Bremmer, F., Pongratanakul, P., Skowron, M. A., Che, Y., Richter, A., Küffer, S., Reuter-Jessen, K., Bohnenberger, H., Pauls, S., Kresbach, C., Schüller, U., Stühler, K., Ströbel, P., Albers, P., & Nettersheim, D. (2023). Characterizing the mutational burden, DNA methylation landscape, and proteome of germ cell tumor-related somatic-type malignancies to identify the tissue-of-origin, mechanisms of therapy resistance, and druggable targets. British Journal of Cancer, 129(10), 1580–1589. https://doi.org/10.1038/s41416-023-02425-5 | |||||||
| Lizenz: |  Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät | |||||||
| Dokument erstellt am: | 26.02.2025 | |||||||
| Dateien geändert am: | 26.02.2025 |
